The inhibition of endothelial DLL4-NOTCH1 signaling by 2'-hydroxyflavanone enhances anti-PD-1 therapy in melanoma [0.03%]
内皮细胞DLL4-NOTCH1信号传导受2'-羟基黄烷酮抑制可增强黑色素瘤的抗PD-1治疗效果
Jihye You,Seunghwan Ha,Doyoung Kim et al.
Jihye You et al.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapeutics; however limited patient responses necessitate combination strategies to improve therapeutic efficacy. Among potential combination partners, drugs targeting DLL4-NO...
Covalent organic frameworks in cancer theranostics: advancing biomarker detection and tumor-targeted therapy [0.03%]
共价有机框架在癌症治疗诊断中的应用：促进生物标志物检测和肿瘤靶向治疗
Sonia Iranpour,Amir Abrishami,Amir Sh Saljooghi
Sonia Iranpour
In recent years, covalent organic frameworks (COFs) have garnered considerable attention in the field of onco-nanotechnology as a new type of nanoporous construct due to their promising physicochemical properties, ease of modification, and ...
Jisoo Kang,Seol Hee Park,Mushira Khanam et al.
Jisoo Kang et al.
Numerous studies have examined the pathophysiological changes induced by chronic alcohol (ethanol) consumption and the underlying mechanisms, while much less attention has been devoted to understanding the health impacts of binge drinking. ...
A novel 11β-HSD1 inhibitor ameliorates liver fibrosis by inhibiting the notch signaling pathway and increasing NK cell population [0.03%]
一个新的11β-HSD1抑制剂通过抑制Notch信号通路和增加NK细胞群来改善肝纤维化
Ji Eun Kim,Yun Kim,Jiwon Bae et al.
Ji Eun Kim et al.
11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) regulates hepatic glucose output and is implicated in liver fibrosis. We aimed to investigate the anti-fibrotic effect of a novel 11β-HSD1 inhibitor in a thioacetamide (TAA)-induced live...
Retraction Note: Anti-inflammatory effect of atorvastatin on vascular reactivity and insulin resistance in fructose fed rats [0.03%]
撤回 notice:阿托伐他汀对果糖喂养的大鼠血管反应性和胰岛素抵抗的抗炎作用
Mona F Mahmoud,Mohamed El-Nagar,Hany M El-Bassossy
Mona F Mahmoud
Discovery of novel naphthalene-based diarylamides as pan-Raf kinase inhibitors with promising anti-melanoma activity: rational design, synthesis, in vitro and in silico screening [0.03%]
一类新型萘胺类泛拉夫激酶抑制剂的发现及其潜在的抗黑色素瘤活性：理性的设计、合成及体内外筛选研究
Ahmed Elkamhawy,Usama M Ammar,Minkyoung Kim et al.
Ahmed Elkamhawy et al.
Raf kinase enzymes are often dysregulated in melanoma. While sorafenib demonstrates strong activity against wild-type B-Raf, it fails to effectively inhibit the mutated form of B-Raf. In this study, sorafenib served as a lead compound for t...
Tumor microenvironment regulation by reactive oxygen species-mediated inflammasome activation [0.03%]
活性氧介导的炎性小体活化对肿瘤微环境的调节作用
Jeong-Hoon Jang,Do-Hee Kim,Kyung-Soo Chun
Jeong-Hoon Jang
Tumor microenvironment (TME) is composed of diverse cell types whose interactions, both direct and indirect, significantly influence tumorigenesis and therapeutic outcomes. Within TME, reactive oxygen species (ROS) are produced by various c...
Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19 [0.03%]
基于生理的药代动力学(PBPK)模型在不同CYP2C9和CYP2C19基因型中对格列齐特的研究
Hye-Jung Park,Sang-Ho Lee,Pureum Kang et al.
Hye-Jung Park et al.
Gliclazide is a sulfonylurea hypoglycemic agent used to treat type 2 diabetes. Cytochrome P450 (CYP) 2C9 and CYP2C19 are primarily involved in the hepatic metabolism of gliclazide. The two CYP isozymes are highly polymorphic, and their gene...
Canine mammary tumors as a promising adjunct preclinical model for human breast cancer research: similarities, opportunities, and challenges [0.03%]
犬乳腺肿瘤作为人类乳腺癌研究的辅助前临床模型的前景：相似性、机遇与挑战
Zeeshan Ahmad Bhutta,Kyung-Chul Choi
Zeeshan Ahmad Bhutta
Despite significant progress in the field of human breast cancer research and treatment, there is a consistent increase in the incidence rate of 0.5 percent annually, posing challenges in the development of effective novel therapeutic strat...
Retraction Note: MiR-338-5p ameliorates pathological cardiac hypertrophy by targeting CAMKIIδ [0.03%]
撤回 notice:MiR-338-5p通过靶向CAMKIIδ改善病理性心脏肥大
Kailong Li,Yuedong Lin,Cong Li
Kailong Li
Retraction of Publication
Archives of pharmacal research. 2025 Jan 2. DOI:10.1007/s12272-024-01530-0 2025